Erythropoietins (Epostim®) during chemoradiotherapy for malignancies in anemic patients
https://doi.org/10.17650/1994-4098-2010-0-3-45-49
Abstract
Anemia in female patients with solid neoplasms is corrected to normalize hemoglobin levels, to increase quality of life, and to improve antitumor therapy tolerance. The clinical application of recombinant human erythropoietin preparations has become an important treat- ment step that permits multiple hemotransfusions to be avoided. Epostim is effective and safe in increasing hemoglobin and packed cell volume and in overcoming the additive toxicity of chemo- and radiotherapy.
About the Authors
V. A. Titova
Russian Radiology Research Center, Ministry of Health and Social Development
Russian Federation
Russian Federation
Yu. M. Kreynina
Russian Radiology Research Center, Ministry of Health and Social Development
Russian Federation
Russian Federation
A. N. Shipilova
Russian Radiology Research Center, Ministry of Health and Social Development
Russian Federation
Russian Federation
L. N. Shevchenko
Russian Radiology Research Center, Ministry of Health and Social Development
Russian Federation
Russian Federation
V. Yu. Petrovsky
Russian Radiology Research Center, Ministry of Health and Social Development
Russian Federation
Russian Federation
I. V. Ose
OOO “Pharmapark”, Moscow
Russian Federation
Russian Federation
T. F. Skobeleva
OOO “Pharmapark”, Moscow
Russian Federation
Russian Federation
A. V. Akimov
OOO “Pharmapark”, Moscow
Russian Federation
Russian Federation
A. L. Badmayev
OOO “Pharmapark”, Moscow
Russian Federation
Russian Federation
References
1. Демидова Л.В. Радиомодификация в сочетанной лучевой терапии рака шейки матки с использованием нетрадиционных режимов фракционирования и лекарственных препаратов. Автореф. дис. ... д-ра мед. наук. М., 2006.
2. Титова В.А., Крейнина Ю.М., Шипилова А.Н. и др. Комплексная коррекция осложнений многокомпонентного лечения злокачественных опухолей различных локализаций с использованием озонотерапии и низкоинтенсированного лазерного излучения. Опух репродукт сист 2009;(3–4):108–12.
3. Bastit L., Vandebroek A., Altintas S. met al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron
4. in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26(10):1611–8.
5. Бесова И.С., Горбунова В.А., Поддубная И.В., Макаренко Н.П. Комбинация таксотера с доксорубицином и циклофосфаном в адъювантной химиотерапии операбельного рака молочной железы на фоне первичной профилактики гранулоцитарными колониестимулирующими факторами. Опух репродукт сист 2009;(3–4):53–8.
6. Howrousian M.R., Kasper C., Oberhoff C. et al. Pathophysiology of cancer-related anemia. In: Erythropoietin in сancer supportive treatment. J.F. Smith et al eds. N.Y.: Marcel Dekker, 1996; p. 13–34.
7. Martin M., Pienkowski T. Mackey J. et al. Adjuvant docetaxel for node-positive brest cancer. N Engl J Vtd 2005;352:2302–13.
Review
For citations:
Titova V.A., Kreynina Yu.M., Shipilova A.N., Shevchenko L.N., Petrovsky V.Yu., Ose I.V., Skobeleva T.F., Akimov A.V., Badmayev A.L. Erythropoietins (Epostim®) during chemoradiotherapy for malignancies in anemic patients. Tumors of female reproductive system. 2010;(3):45-49. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-3-45-49
Views:
621
Email this article 